View Press Release
Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of eye disorders.
Nyxol® Eye Drops is a once-daily preservative-free eye drop formulation designed to reduce pupil size and improve visual acuity.
APX3330 is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammatory pathways relevant to retinal and choroidal vascular diseases.
Ocuphire Pharma plans to initiate two Phase 3 registration trials in the fourth quarter of 2020, and two Phase 2 trials in the first quarter of 2021.
Jul 22, 2021 8:00am EDT
Jul 13, 2021 9:00am EDT
Jul 9, 2021 5:00pm EDT
Jun 30, 2021 7:15am EDT
Stay informed and receive company updates straight to your inbox.